Pharmaceutical company AbbVie (NYSE: ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.

Is now the time to buy ABBV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that “each [portfolio] delivered growth above 20%,” with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure on legacy products and a competitive landscape in key markets.

Looking ahead, AbbVie’s reduced full-year profit guidance is shaped by anticipated dilution from the planned Apogee Therapeutics acquisition and ongoing investments in pipeline expansion. Management pointed to upcoming regulatory milestones for new indications, including SKYRIZI in Crohn’s disease and RINVOQ in dermatology, as well as the launch of Tevapadon in Parkinson’s disease. CFO Scott Reents noted, “Our updated outlook reflects both strong momentum in key products and the anticipated impact of the Apogee transaction.” The company also highlighted potential margin pressure from increased R&D and commercial expenses tied to these initiatives.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to high demand for immunology and neuroscience therapies, successful new product launches, and strategic pipeline investments, while also noting the effect of competitive pressure and portfolio transitions.

• Immunology growth leadership: SKYRIZI and RINVOQ drove segment momentum, with management highlighting SKYRIZI’s continued market share gains in psoriasis and IBD, and new pediatric approvals. RINVOQ’s label expansions in Europe for vitiligo and alopecia areata were also cited as growth contributors.
• Neuroscience momentum: The neuroscience segment, led by Vraylar, QLIPTA, and Vialev, delivered strong results, with Vialev on track for blockbuster status. Management emphasized upcoming launches, including Tevapadon for Parkinson’s disease, as pivotal for sustaining growth.
• Oncology transition: While total oncology revenue declined due to competitive and IRA pricing pressures on IMBRUVICA, newer therapies such as VENCLEXTA and the recently approved Decnapaz (for rare blood cancers) partially offset headwinds. Management underscored the potential of its antibody-drug conjugate (ADC) pipeline.
• Pipeline and business development: The planned acquisition of Apogee Therapeutics is expected to strengthen AbbVie’s immunology pipeline, adding differentiated assets in dermatology and respiratory diseases. Management signaled further business development activity as a strategic priority.
• Aesthetics market dynamics: The aesthetics division faced continued softness in dermal fillers but saw modest growth in Botox Cosmetic and successful launches of new products like Bowie, a novel short-acting toxin approved in Europe and Canada. Management indicated ongoing investments to address underpenetrated markets.

Drivers of Future Performance

Management’s outlook centers on continued momentum for core immunology and neuroscience drugs, while addressing competitive headwinds, integration of pipeline assets, and margin pressures from R&D and commercial investments.

• Pipeline expansion and launches: Upcoming regulatory decisions for SKYRIZI’s subcutaneous induction in Crohn’s disease, RINVOQ’s U.S. approvals in dermatology, and the launch of Tevapadon in Parkinson’s disease are expected to drive revenue growth. Management expects these launches to expand the addressable market and reinforce AbbVie’s leadership in key therapeutic areas.
• Integration of Apogee Therapeutics: The Apogee acquisition introduces new assets in immunology, particularly in dermatology and respiratory diseases. Management anticipates near-term dilution to earnings but expects these assets to contribute materially to revenue and pipeline depth in the coming years.
• Margin and cost dynamics: Increased R&D and commercial expenses associated with business development, new product launches, and expanded field forces are likely to pressure operating margins. Management remains focused on balancing investment with financial discipline, emphasizing the need to achieve targeted net leverage following the Apogee deal.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will monitor (1) the outcome of regulatory reviews for SKYRIZI’s subcutaneous induction and new dermatology indications for RINVOQ, (2) the commercial launch progress of Tevapadon in Parkinson’s disease and Bowie in aesthetics, and (3) the integration of Apogee Therapeutics and the impact of new immunology assets. Progress in the oncology pipeline and margin management will also be key indicators.

AbbVie currently trades at $251.70, down from $257.40 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.